Cardiovascular medication use following percutaneous coronary intervention: the Australian experience.

about

Evidence-based interventions in primary care following acute coronary syndrome in Australia and New Zealand: a systematic scoping review

P2860

Q36187786-9B57B675-DB70-4B5E-8DF7-1B0CB5D6621B

P2860

Cardiovascular medication use following percutaneous coronary intervention: the Australian experience.

Item

http://www.wikidata.org/entity/Q38176088

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Cardiovascular medication use ...... on: the Australian experience.

@en

type

Item

label

Cardiovascular medication use ...... on: the Australian experience.

@en

prefLabel

Cardiovascular medication use ...... on: the Australian experience.

@en

P1476

Cardiovascular medication use ...... on: the Australian experience.

@en

P2093

Alexander Black

http://www.w3.org/2001/XMLSchema#string

Andrew E Ajani

http://www.w3.org/2001/XMLSchema#string

Angela L Brennan

http://www.w3.org/2001/XMLSchema#string

Bryan P Yan

http://www.w3.org/2001/XMLSchema#string

Christopher M Reid

http://www.w3.org/2001/XMLSchema#string

David J Clark

http://www.w3.org/2001/XMLSchema#string

Gishel New

http://www.w3.org/2001/XMLSchema#string

James Shaw

http://www.w3.org/2001/XMLSchema#string

Justin A Cole

http://www.w3.org/2001/XMLSchema#string

Matias B Yudi

http://www.w3.org/2001/XMLSchema#string

P2860

International data on supportive therapies at 1 year in acute coronary syndrome patients undergoing PCI: results from the APTOR study.

Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction--a hospital registry-primary care linked cohort (MINAP-GPRD).

Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Differences in the use of guideline-recommended therapies among 14 European countries in patients with acute coronary syndromes undergoing PCI.

Determinants of risk factor control in subjects with coronary heart disease: a report from the EUROASPIRE III investigators.

Impact of acute and chronic risk factors on use of evidence-based treatments in patients in Australia with acute coronary syndromes.

A National Cardiac Surgery Database: current achievements and future challenges.

Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous co

Gender differences in the implementation of cardiovascular prevention measures after an acute coronary event.

Age and sex differences, and changing trends, in the use of evidence-based therapies in acute coronary syndromes: perspectives from a multinational registry.

P304

47-51

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/1755-5922.12060

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24393169

http://www.w3.org/2001/XMLSchema#string

Cardiovascular medication use following percutaneous coronary intervention: the Australian experience.

about

P2860

P2860

Cardiovascular medication use following percutaneous coronary intervention: the Australian experience.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698